

SARS-CoV-2 IgG, Spike

Order Name: **CoV2 IgG Spike**

Test Number: 6907251

Revision Date: 10/01/2022

TEST NAME	METHODOLOGY	LOINC CODE
SARS-CoV2 IgG Spike	Chemiluminescent Micropartical Immunoassay	94505-5
SARS-CoV2 IgG Spike Index	Calculation	

SPECIMEN REQUIREMENTS				
Specimen	Specimen Volume (min)	Specimen Type	Specimen Container	Transport Environment
Preferred	2 mL (0.5 mL)	Serum	Clot Activator SST	Refrigerated
Instructions	Stability: Ambient 2 days; Refrigerated 7 days; Freeze if testing will be delayed more than 7 days			

GENERAL INFORMATION	
Testing Schedule	Mon-Fri
Expected TAT	1-2 Days
Clinical Use	RML has initiated two assays for the semi-quantitative detection of IgG antibodies to the COVID 19 nucleocapsid and a second to the COVID 19 spike protein. The IgG antibodies to the nucleocapsid can only come about following a SARS-CoV-2 infection. IgG antibodies to the spike protein will follow an infection and/or a vaccination with a spike initiating vaccine. The assays will be valuable in discerning as to whether the patient has or has not had a COVID 19 infection or a vaccination. The semi-quantitative values will be important to determine the degree of antibody activity in seroconversion as well as following the status of the levels of antibody activity over time. They will be available in two formats. One is the COVID 19 IgG anti-spike and the other is COVID 19 IgG anti-nucleocapsid. The results will be reported as a relative value (i.e. positive or negative) as well as a semi-quantitative value.
Notes	Testing for IgG Spike protein antibody to the novel Coronavirus (SARS-CoV-2/COVID-19) performed at Labcorp Oklahoma, Inc. Central Lab
CPT Code(s)	86769
Lab Section	Immunology - Chemistry